Hypoglycemia or a below normal blood sugar level is a common complication of diabetes. The condition can also arise due to prolonged starvation, certain hormonal disorders such as hypopituitarism and ...

School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...

IN the majority of infants with chronic hypoglycemia the specific origin of the disorder cannot be identified. Regardless of etiology, correction of the hypoglycemia is essential to prevent mental ...

Glucagon is underused for treating severe hypoglycemia in both emergency and outpatient settings, new research suggests. Findings from an analysis of data on glucagon administration by emergency ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...

The submission is supported by three phase 3 trials in adult and pediatric patients that showed dasiglucagon met the primary and all key secondary end points. A New Drug Application (NDA) has been ...

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg (Reuters) - The U.S. Food and Drug Administration ...

Researchers have shown that a targeted treatment they developed is effective at controlling blood sugar in patients with hyperinsulinism (HI), a genetic disease in which the pancreas produces too much ...

Treatment of factitious hypoglycemia, whether it is insulin- or sulfonylurea-induced, takes place in 2 stages. [3] The first stage involves relieving the neuroglycopenic symptoms by restoring the low ...

The overall incidence of hypoglycemia was considerable in this large working-age population and was associated with $52 million (2008 dollars) in direct medical costs. The cohort was composed of ...

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...